Active Ingredient(s): Acalabrutinib
FDA Approved: * October 31, 2017
Pharm Company: * ACERTA PHARMA BV
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Calquence Overview

Acalabrutinib (trade name Calquence) is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma.[2] Specifically it is for people who had previously been treated with another therapy.[3] As of 2019, it was unclear whether it improved outcomes.[2] Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells.[2] It is a second generation Bruton's...

Read more Calquence Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Calquence Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Calquence: (1 result)

Sorted by National Drug Code
  • 0310-0512 Calquence 100 mg Oral Capsule, Gelatin Coated by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Acalabrutinib or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA